Optimizing dendritic cell-based approaches for cancer immunotherapy.

摘要: Dendritic cells (DC) are professional antigen-presenting uniquely suited for cancer immunotherapy. They induce primary immune responses, potentiate the effector functions of previously primed T-lymphocytes, and orchestrate communication between innate adaptive immunity. The remarkable diversity cytokine activation regimens, DC maturation states, antigen-loading strategies employed in current DC-based vaccine design reflect an evolving, but incomplete, understanding optimal immunobiology. In clinical realm, existing immunotherapy efforts have yielded encouraging inconsistent results. Despite recent U.S. Federal Drug Administration (FDA) approval sipuleucel-T metastatic castration-resistant prostate cancer, clinically effective as monotherapy a majority tumors remains distant goal. Recent work has identified that may allow more potent “next-generation” vaccines. Additionally, multimodality approaches incorporating improve outcomes.